Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis-Reference-Cited by-同舟云学术

Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis

Published:2021-11-02 Issue: Volume: Page:1-8
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Chen Xuan¹,Yang Zhiguang¹²,Xiang Guiyuan¹,Gu Lingna¹,Qi Ziheng³,Wan Bin⁴,Lu Yun¹,Chang Feng¹,Zhu Yumei¹^ORCID

Affiliation:

1. School of International Pharmaceutical Business, China Pharmaceutical University, Jiangsu, China

2. Department of Healthcare Reform, National Health Commission of the People’s Republic of China, Beijing, China

3. Nanjing Foreign Language School, Nanjing, China

4. Department of Health Insurance Management, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China

Funder

National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2022.1993062

Reference49 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey

3. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

4. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

5. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of consolidation durvalumab for inoperable stage III non-small cell lung cancer in Vietnam;BMJ Open;2024-08

2. Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the context of the Chilean health care system;PLOS ONE;2024-07-26

3. A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China;PLOS ONE;2023-06-01

4. Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial;Cost Effectiveness and Resource Allocation;2023-03-01

5. Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model;Frontiers in Public Health;2023-02-24